ETFs with BMY as a Top 10 Holding*Sponsored by:
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|6.49%||iShares Dow Jones U.S. Pharmaceutical Index Fund (IHE)||+16.07 (18.75%)|
|5.26%||PowerShares Dynamic Pharmaceuticals (PJP)||+7.95 (22.80%)|
|4.7%||Merrill Lynch Pharmaceutical HOLDRS (PPH)||+5.85 (14.17%)|
|4.58%||SPDR S&P Pharmaceuticals ETF (XPH)||+12.66 (22.44%)|
|3.89%||First Trust Morningstar Dividend Leaders Index Fund (FDL)||+3.10 (16.68%)|
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.
Company Description (as filed with the SEC)
Bristol-Myers Squibb Company (which may be referred to as Bristol-Myers Squibb, BMS, the Company, we, our or us) was incorporated under the laws of the State of Delaware in August 1933 under the name Bristol-Myers Company, as successor to a New York business started in 1887. In 1989, Bristol-Myers Company changed its name to Bristol-Myers Squibb Company as a result of a merger. We are engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Over the last few years, we executed our strategy to transform into a next generation biopharmaceutical company. This transformation encompassed all areas of our business and operations. As part of this strategy, we have divested our non-pharmaceutical businesses, implemented our acquisition and licensing strategy known as the “string-of-pearls”, and executed our productivity transformation initiative (PTI). ... More ...